News

Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Piper Sandler Lifts PT on Verona Pharma (VRNA) Stock, Maintains Overweight
Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Piper ...
BioPharma Dive3h
With Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
These Stocks Are Moving the Most Today: Nvidia, AES, Verona Pharma, WPP, Bloom Energy, Aehr Test Systems, and More
Nvidia’s valuation crosses $4 trillion during Wednesday’s session, while AES stock rises sharply following a report that says ...
Raleigh pharma's $10B sale pays off for Boston, NY investment firms
Investment firms in Boston and New York could see the biggest gains from the sale of a Raleigh drugmaker. Raleigh firm rides ...
Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration
Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...
STAT2d
Pharmalittle: We’re reading about Trump’s latest tariff threat, a Merck deal, and lots more
President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...
Merck nears about $10 billion deal for London-based lung therapy firm Verona, FT reports
U.S. drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...